Company Overview of Cahaba Pharmaceuticals, LLC
Cahaba Pharmaceuticals, LLC, a biotech company, develops oncology therapeutics and supportive care products for cancer patients. Its products include dihydropyrimidine dehydrogenase inhibitor for the treatment of hand-foot syndrome; and triciribine phosphate monohydrate, a nucleoside analog inhibition of AKT, a key component of a signaling pathway to promote cancer cell growth and survival, and resistance to chemotherapy and radiotherapy. It has exclusive rights in North America and Asia. The company was founded in 2008 and is based in Princeton, New Jersey.
103 Carnegie Center
Princeton, NJ 08540
Founded in 2008
Key Executives for Cahaba Pharmaceuticals, LLC
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Cahaba Pharmaceuticals, LLC, please visit www.cahabapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.